NASDAQ:ATHX Athersys (ATHX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Athersys Stock (NASDAQ:ATHX) Get Athersys alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2 shsAverage Volume1.77 million shsMarket Capitalization$833 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Athersys, Inc. was a Cleveland-based biotechnology company focused on regenerative medicine and cell therapies for serious medical conditions. Founded in 1995, the company developed investigational treatments rather than marketed products. Its leading program was MultiStem, an off-the-shelf cell therapy made from multipotent adult progenitor cells. Athersys studied MultiStem in clinical trials for conditions including ischemic stroke and acute respiratory distress syndrome; it was not an approved commercial treatment. Athersys collaborated with Japan-based Healios on the development of MultiStem. After Athersys filed for Chapter 11 bankruptcy protection in 2023, Healios acquired substantially all of the company’s assets related to the program.AI Generated. May Contain Errors. Read More Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATHX Stock News HeadlinesAthersys to Sell Most Assets to HealiosJanuary 8, 2024 | marketwatch.comAthersys Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 16, 2023 | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)Athersys shares migrate to Pink marketplace for broker-to-broker tradingOctober 23, 2023 | bizjournals.comAthersys shares delisted by Nasdaq Stock MarketOctober 20, 2023 | bizjournals.comAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesOctober 16, 2023 | finance.yahoo.comAthersys crashes after bankruptcy warningOctober 10, 2023 | msn.comAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with HealiosOctober 10, 2023 | finance.yahoo.comSee More Headlines ATHX Stock Analysis - Frequently Asked Questions How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($2.00) by $0.25. The biopharmaceutical company had revenue of $4.79 million for the quarter. When did Athersys' stock split? Athersys's stock reverse split on Monday, August 29th 2022.The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Dynavax Technologies (DVAX), Bank of America (BAC), Novavax (NVAX) and Micron Technology (MU). Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ATHX CIK1368148 Webwww.athersys.com Phone(216) 431-9900Fax216-361-9495Employees24Year Founded1995Profitability EPS (Trailing Twelve Months)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.53 million Net MarginsN/A Pretax Margin-46,304.93% Return on EquityN/A Return on Assets-223.03% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual Sales$146 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.33) per share Price / BookN/AMiscellaneous Outstanding Shares61,719,000Free Float61,700,000Market Cap$833 thousand OptionableNo Data Beta-0.90 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ATHX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.